Financial Performance - Total sales for the three months ended September 30, 2024, were $243,971 thousand, representing a 31.5% increase from $185,622 thousand in the same period of 2023[6] - Gross profit for the nine months ended September 30, 2024, was $332,119 thousand, up 21.0% from $274,395 thousand in the prior year[6] - Operating loss for the three months ended September 30, 2024, was $(26,093) thousand, an improvement from $(31,545) thousand in the same quarter of 2023[6] - Net loss for the nine months ended September 30, 2024, was $(96,780) thousand, compared to $(192,609) thousand for the same period in 2023, indicating a significant reduction in losses[6] - Revenue for the three months ended September 30, 2024, was $243.9 million, up 31% from $185.6 million in the same period of 2023[112] - Sales of insulin pumps for the three months ended September 30, 2024, reached $114.8 million, a 30% increase compared to $88.0 million in 2023[112] - For the nine months ended September 30, 2024, the company shipped nearly 87,000 pumps worldwide, generating sales of $657.6 million, compared to $550.9 million for the same period in 2023, representing an increase of approximately 19%[170] - Pump sales in the United States increased by nearly 10% to $230.2 million for the nine months ended September 30, 2024, compared to $207.2 million for the same period in 2023[171] Assets and Liabilities - Total current assets increased to $752,826 thousand as of September 30, 2024, from $747,989 thousand at the end of 2023[4] - Total liabilities rose to $720,020 thousand as of September 30, 2024, compared to $639,026 thousand at the end of 2023, reflecting increased financial obligations[4] - Cash and cash equivalents decreased to $49,039 thousand from $58,868 thousand at the end of 2023, indicating a decline in liquidity[4] - Stockholders' equity decreased to $237,710 thousand as of September 30, 2024, from $313,632 thousand at the end of 2023, reflecting the impact of net losses[4] - As of September 30, 2024, total assets amounted to $463,096,000, with cash equivalents at $38,830,000 and United States Treasury securities at $112,609,000[55] Research and Development - Research and development expenses for the three months ended September 30, 2024, were $51,107 thousand, up 21.7% from $41,970 thousand in the same period of 2023[6] - Research and development expenses increased by 15% to $146.7 million for the nine months ended September 30, 2024, compared to $127.1 million for the same period in 2023[178] Stock-Based Compensation - Stock-based compensation expense increased to $73,217 for the nine months ended September 30, 2024, up from $65,335 in the previous year[14] - Total stock-based compensation expense for the three months ended September 30, 2024, was $26.3 million, an increase of 27% from $20.7 million in the same period of 2023[100] Cash Flow - The company reported a net cash used in operating activities of $13,508 for the nine months ended September 30, 2024, compared to a net cash used of $24,594 in the same period of 2023[14] - The company recorded a cash decrease of $9,829 for the nine months ended September 30, 2024, compared to a decrease of $92,906 in the same period of 2023[14] - Net cash provided by operating activities was $13.5 million for the nine months ended September 30, 2024, compared to cash used of $24.6 million in the same period in 2023[185] Product Development and Sales - The company expanded its insulin pump portfolio to include the t:slim X2 and Tandem Mobi, both featuring Control-IQ technology for advanced insulin delivery management[16] - The Tandem Mobi insulin pump, launched in February 2024, is the world's smallest durable automated insulin delivery system, designed for greater discretion and flexibility[127] - The company plans to introduce the t:slim X3, which will feature enhanced technology, greater processing power, and improved battery life[132] - The company is developing extended wear infusion set technology to enhance user experience and reduce waste[134] Market and Competition - The company relies heavily on sales of insulin pump products, which generate a significant portion of its revenue, making it vulnerable to factors that may negatively impact these sales[202] - The company faces risks related to competition, which may render its products obsolete or less desirable[203] Acquisitions and Investments - The Company completed the acquisition of AMF Medical for a total consideration of approximately CHF 70.4 million, including contingent earnout payments of up to CHF 129.6 million[114] - The company plans to invest an additional $46.4 million in a private company, expected to close in Q4 2024, which will represent over 20% of the investee's outstanding equity[27] Regulatory and Compliance - Regulatory approvals and actions may impact the company's ability to expand its customer base and bring products to market[138] - The company maintains effective disclosure controls and procedures, ensuring timely and accurate reporting of financial information[196] - The company has not experienced any material changes in its internal control over financial reporting during the quarter ended September 30, 2024[198]

Exhibit 99.1 FOR IMMEDIATE RELEASE Third Quarter 2024 Highlights Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, November 6, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales ...

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 21.7% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Stock Performance and Indicators - TNDM's Relative Strength Index (RSI) reading is at 29.87, indicating that the heavy selling pressure may be exhausting, suggesting a possible bounce back towards previous supply and demand equilibrium [3]. - The stock is considered oversold when its RSI falls below 30, which is a common threshold for identifying potential price reversals [2]. Group 2: Earnings Estimates and Analyst Consensus - There is strong consensus among sell-side analysts that earnings estimates for TNDM have increased by 0.1% over the last 30 days, indicating a positive outlook for the company's financial performance [4]. - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [4].

Flat revenue growth might be in store for the company in a very crucial market. An analyst issued the equivalent of a warning on Tandem Diabetes Care (TNDM -3.16%) stock on the second trading day of the week and, absent any other news for the company, some investors traded out of it. This left Tandem's shares with a more than 3% loss in price on the day, which compared unfavorably to the sub-1% decline of the bellwether S&P 500 index. Citi advises keeping watch on the stock The prognosticator behind that pi ...

Tandem Diabetes Care (TNDM) has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly's ultra-rapid acting insulin, Lyumjev, in the European Union (EU). The compatibility with Lyumjev offers new possibilities in the insulin delivery landscape, enhancing the efficacy of Tandem's automated insulin delivery (AID) systems. This latest development strengthens Tandem's position in the diabetes technology market and enhances its offerings for individuals with ...

Tandem Diabetes (TNDM) is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough competition pose challenges. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving TNDM Stock Tandem Diabetes seeks to grow its business through the acquisition of products or technologies or investments in businesses. Last year, it acquired Swiss-based AMF Medical SA — the developer of the Sigi Patch Pump. The company's speed-to-market with Continuous Glucose Monitoring (CGM) ...

Tandem Diabetes Care, Inc.'s (TNDM) flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company's (LLY) Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). The development follows a clinical study that reported high satisfaction and quality of life benefits by pairing Lyumjev with Control-IQ technology. Ultra-rapid acting insulin is a popular choice for people living with diabetes b ...

At a stroke, it's got a product authorized for a specific use in 27 countries. Tandem Diabetes Care (TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the headlines investors piled into the stock. At the end of the day the highly specialized healthcare company's share price had risen in excess of 4%, good enough to top the 1.7% rise of the benchmark S&P 500 index. Crucial approval granted Tandem announced Thursday morning that it had won an important approval ...

Tandem Diabetes Care, Inc.'s (TNDM) growth is backed by its impressive range of new products. The flourishing diabetes market provides a favorable opportunity for the company's growth. However, concerns loom over Tandem Diabetes' substantial reliance on insulin pumps and the adverse impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) company has surged 56.2% compared with 10.9% growth of the industry and a 24.9% rise of the S&P 500 composite. The renowned medical device company h ...

Tandem Diabetes (TNDM) is gaining from continued product innovations. Yet, rising costs put pressure on margins. The stock carries a Zacks Rank #3 (Hold). Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. During the second quarter, its flagship t:slim X2 insulin pump software became compatible with Dexcom G7. It was already compatible with Dexcom G6 Continuous Glucose Monitoring (CGM) systems. Following this developme ...